Sclerostin (encoded by the SOST gene) is a secreted glycoprotein primarily produced by osteocytes. It acts as a key negative regulator of bone formation by binding to LRP5/6 co-receptors, thereby inhibiting the osteoanabolic Wnt/beta-catenin signaling pathway. Targeting the SOST pathway represents a highly validated therapeutic strategy for severe osteoporosis, bone fracture healing, and osteogenesis imperfecta. Developing high-affinity antagonists requires robust assays to verify LRP5/6 blocking efficiency, cross-species reactivity, and downstream Wnt pathway activation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SOST drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SOST Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation and folding. |
View SOST Products |
| Gene Delivery | SOST Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression validation. |
View SOST Products |
| Benchmark Ab | Anti-SOST Recombinant Antibody Sequence derived from Romosozumab. Premium positive control for binding and functional assays. |
View SOST Products |
| Validator | SOST siRNA Set Target-specific knockdown verification in osteoblast-like cell lines. |
View SOST Products |
| Related Target A | LRP5 Primary functional receptor partner for Sclerostin; critical for competitive binding assays. |
View LRP5 Products |
| Related Target B | DKK1 Synergistic Wnt pathway inhibitor; co-targeting SOST/DKK1 enhances bone anabolic activity. |
View DKK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog SOST proteins available with >95% purity |
| Wnt signaling pathway screening | High-purity LRP5/LRP6 extracellular domain proteins strictly verified by mass spec for binding assays |
| Lack of Controls | Clinical Benchmark Antibodies (Romosozumab biosimilar) included for functional validation |
| False Positives | Validated siRNA included for target-specific knockdown and assay specificity checks |
Live SOST R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SOST therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to bispecific modalities and bone-targeted drug delivery systems. As first-generation therapies like Romosozumab reach the clinic and gain widespread approval, the next wave of R&D is targeting synergistic mechanisms (such as SOST/DKK1 bispecific antibodies) to achieve superior bone-building efficacy while minimizing systemic cardiovascular risks associated with complete Wnt pathway modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Amgen, UCB, Biosimilar developers | Postmenopausal Osteoporosis, Osteopenia | LRP5/6 competitive binding assay (Requires high-purity HEK293-expressed SOST) |
| Bispecific Antibody | Amgen, GSK, Academic Institutes | Severe Bone Fractures, Rare Bone Diseases | Dual-targeting validation (Requires simultaneous binding assays with SOST and DKK1) |
| Small Molecule / RNAi | Preclinical stage biotech firms | Osteogenesis Imperfecta, Local Bone Healing | Target knockdown and gene silencing validation (Requires sequence-verified siRNA panels) |